Viking Therapeutics Inc (VKTX) concluded trading on Thursday at a closing price of $28.68, with 4.29 million shares of worth about $122.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.88% during that period and on March 06, 2025 the price saw a gain of about 2.65%. Currently the company’s common shares owned by public are about 111.57M shares, out of which, 108.93M shares are available for trading.
Stock saw a price change of 0.03% in past 5 days and over the past one month there was a price change of -11.40%. Year-to-date (YTD), VKTX shares are showing a performance of -28.73% which decreased to -68.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.41 but also hit the highest price of $96.74 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 4.34 million. The stock is currently trading -3.43% below its 20-day simple moving average (SMA20), while that difference is down -16.00% for SMA50 and it goes to -45.22% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 111.57M outstanding shares and institutions hold larger chunk of about 73.72% of that.
The stock has a current market capitalization of $3.22B and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 33.09 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 10.06% while standing at 8.81% over the month.
Stock’s fiscal year EPS is expected to drop by -57.96% while it is estimated to decrease by -35.30% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on February 13, 2025 offering a Sector outperform rating for the stock and assigned a target price of $102 to it. Coverage by Citigroup stated Viking Therapeutics Inc (VKTX) stock as a Neutral in their note to investors on February 07, 2025, suggesting a price target of $38 for the stock. On December 02, 2024, Piper Sandler Initiated their recommendations, while on November 22, 2024, B. Riley Securities Initiated their ratings for the stock with a price target of $109. Stock get a Buy rating from H.C. Wainwright on November 04, 2024.
